ReviewCurrent oncology reports2025
Hereditary Hematopoietic Malignancies: Considerations for Optimizing Diagnosis and Management.
Review in Current oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A complete blood count-based machine learning model for rapid differentiation of aplastic anemia, immune thrombocytopenia, and myelodysplastic syndromes in routine clinical practice.Practical laboratory medicine · 2026Article
- Performance and clinical utility of Spanish germ line genetic testing criteria for hematologic neoplasms predisposition.Blood advances · 2026Article
- Germline DDX41 mutations in myeloid neoplasms: a comprehensive review.The Korean journal of internal medicine · 2026Review
- Targeting RUNX1 Germline Variants: Agents Under Investigation.Current hematologic malignancy reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewHereditary hematopoietic malignancies (HHMs) were once considered extremely rare. As diagnostic testing indications and methods have evolved, deleterious germline variants associated with increased risk of developing hematopoietic malignances are recognized increasingly. The purpose of this review is to summarize recent advances in knowledge, diagnostic, and treatment approaches for several well-known HHM predisposition disorders. RECENT
findingsPatients often lack classic signs and symptoms typically associated with HHMs, may present at any age, and may not have a suggestive family history. Early identification of causative variants allows for timely anticipatory guidance for patients and family members and has important implications for optimizing treatment decisions. HHMs are not rare. With expanded genetic testing along with appropriate germline tissue selection and ancillary testing, predisposition variants can be identified early and inform appropriate surveillance and treatment decisions for patients and their families.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.